Reducing the Harm of Medication - Recent Trends in Pharmacovigilance, Volume II PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Reducing the Harm of Medication - Recent Trends in Pharmacovigilance, Volume II PDF full book. Access full book title Reducing the Harm of Medication - Recent Trends in Pharmacovigilance, Volume II by Elena Ramírez. Download full books in PDF and EPUB format.
Author: Elena Ramírez
Publisher: Frontiers Media SA
ISBN: 2832522246
Category : Medical
Languages : en
Pages : 132
Get Book
Book Description
Author: Elena Ramírez
Publisher: Frontiers Media SA
ISBN: 2832522246
Category : Medical
Languages : en
Pages : 132
Get Book
Book Description
Author: Elena Ramírez
Publisher: Frontiers Media SA
ISBN: 2832501915
Category : Science
Languages : en
Pages : 165
Get Book
Book Description
Author: World Health Organization
Publisher:
ISBN: 9789290360742
Category : Medical
Languages : en
Pages : 381
Get Book
Book Description
In spite of recent progress in the harmonization of terminology and processes affecting work on the clinical safety of medicines consensus is needed on standards for many difficult aspects of day-to-day pharmacovigilance that continue to pose problems for both the pharmaceutical industry and drug regulators. The CIOMS V Working Group has generated proposals for pragmatic approaches to dealing with such issues as: classification and handling of individual safety case reports from a variety of sources (spontaneous consumer reports solicited reports literature the Internet observational studies and secondary data bases disease and other registries regulatory ADR databases and licensor-licensee interactions); new approaches to case management and regulatory reporting practices (proper clinical evaluation of cases incidental vs other events patient and reporter identifiability seriousness criteria expectedness criteria case follow-up criteria and the role and structure of case narratives); improvements and efficiencies in the format content and reporting of periodic safety update reports (PSURs) (including results of an industry survey on PSUR workloads and practices; proposals for high case volume and long time-period reports simplification of certain PSURs summary bridging reports addendum reports license renewal reports for EU and Japan dealing with old products and other technical details); determination and use of population exposure (denominator) data (sources of data and a guide to analytical approaches for a variety of circumstances).The Group has also taken stock of the current state of expedited and periodic clinical safety reporting requirements around the world with summary data on regulations from more than 60 countries. Recommendations are made for enhancing the harmonization steps already taken as a result of previous CIOMS publications and the ICH process. In addition to dealing with unfinished and unresolved issues from previous CIOMS initiatives the report covers many emerging topics such as those involving new technologies. Its 20 Appendices provide a wealth of detailed explanations and reference information. It is the most comprehensive and recent treatment of difficult pharmacovigilance issues affecting the working practices and systems of drug safety and other pharmaceutical professionals.
Author: Agency for Healthcare Research and Quality/AHRQ
Publisher: Government Printing Office
ISBN: 1587634333
Category : Medical
Languages : en
Pages : 396
Get Book
Book Description
This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.
Author: Council for International Organizations of Medical Sciences (CIOMS)
Publisher: Cioms
ISBN: 9789290360827
Category : Drug monitoring
Languages : en
Pages : 0
Get Book
Book Description
In recent years public expectations for rapid identification and prompt management of emerging drug safety issues have grown swiftly. Over a similar timeframe, the move from paper-based adverse event reporting systems to electronic capture and rapid transmission of data has resulted in the accrual of substantial datasets capable of complex analysis and querying by industry, regulators and other public health organizations. These two drivers have created a fertile environment for pharmacovigilance scientists, information technologists and statistical experts, working together, to deliver novel approaches to detect signals from these extensive and quickly growing datasets, and to manage them appropriately. In following this exciting story, this report looks at the practical consequences of these developments for pharmacovigilance practitioners. The report provides a comprehensive resource for those considering how to strengthen their pharmacovigilance systems and practices, and to give practical advice. But the report does not specify instant solutions. These will inevitably be situation specific and require careful consideration taking into account local needs. However, the CIOMS Working Group VIII is convinced that the combination of methods and a clear policy on the management of signals will strengthen current systems. Finally, in looking ahead, the report anticipates a number of ongoing developments, including techniques with wider applicability to other data forms than individual case reports. The ultimate test for pharmacovigilance systems is the demonstration of public health benefit and it is this test which signal detection methodologies need to meet if the expectations of all stakeholders are to be fulfilled.
Author: Stephen J. Mayall
Publisher: Elsevier
ISBN: 1908818271
Category : Medical
Languages : en
Pages : 448
Get Book
Book Description
Therapeutic risk management of medicines is an authoritative and practical guide on developing, implementing and evaluating risk management plans for medicines globally. It explains how to assess risks and benefit-risk balance, design and roll out risk minimisation and pharmacovigilance activities, and interact effectively with key stakeholders. A more systematic approach for managing the risks of medicines arose following a number of high-profile drug safety incidents and a need for better access to effective but potentially risky treatments. Regulatory requirements have evolved rapidly over the past decade. Risk management plans (RMPs) are mandatory for new medicinal products in the EU and a Risk Evaluation and Mitigation Strategy (REMS) is needed for certain drugs in the US. This book is an easy-to-read resource that complements current regulatory guidance, by exploring key areas and practical implications in greater detail. It is structured into chapters encompassing a background to therapeutic risk management, strategies for developing RMPs, implementation of RMPs, and the continuing evolution of the risk management field.The topic is of critical importance not only to the pharmaceutical and biotechnology industries, but also regulators and healthcare policymakers.Some chapters feature contributions from selected industry experts. An up-to-date practical guide on conceiving, designing, and implementing global therapeutic risk management plans for medicines A number of useful frameworks are presented which add impact to RMPs (Risk Management Plans), together with regional specific information (European Union, United States, and Japan) A comprehensive guide for performing risk management more effectively throughout a product’s life-cycle
Author: Victor R. Preedy
Publisher: Academic Press
ISBN: 0128006773
Category : Science
Languages : en
Pages : 1106
Get Book
Book Description
Neuropathology of Drug Addictions and Substance Misuse, Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions is the third of three volumes in this informative series and offers a comprehensive examination of the adverse consequences of the most common drugs of abuse. Each volume serves to update the reader’s knowledge on the broader field of addiction as well as to deepen understanding of specific addictive substances. Volume 3 addresses prescription medications, caffeine, polydrug misuse, and non-drug addictions. Each section provides data on the general, molecular, cellular, structural, and functional neurological aspects of a given substance, with a focus on the adverse consequences of addictions. Research shows that the neuropathological features of one addiction are often applicable to those of others, and understanding these commonalties provides a platform for studying specific addictions in more depth and may ultimately lead researchers toward new modes of understanding, causation, prevention and treatment. However, marshalling data on the complex relationships between addictions is difficult due to the myriad of material and substances. Offers a modern approach to understanding the pathology of substances of abuse, offering an evidence-based ethos for understanding the neurology of addictions Fills an existing gap in the literature by serving as a “one-stop-shopping synopsis of everything to do with the neuropathology of drugs of addiction and substance misuse Includes in each chapter: list of abbreviations, abstract, introduction, applications to other addictions and substance misuse, mini-dictionary of terms, summary points, 6+ figures and tables, full references Offers coverage of preclinical, clinical, and population studies, from the cell to whole organs, and from the genome to whole body
Author: Mireia Solerdelcoll
Publisher: Frontiers Media SA
ISBN: 2832541798
Category : Medical
Languages : en
Pages : 97
Get Book
Book Description
Author: Sharadini Arun Dahanukar
Publisher: Popular Prakashan
ISBN: 9788171540969
Category :
Languages : en
Pages : 188
Get Book
Book Description
Author: Farid A. Badria
Publisher: BoD – Books on Demand
ISBN: 1839685204
Category : Medical
Languages : en
Pages : 236
Get Book
Book Description
Drug repurposing or drug repositioning is a new approach to presenting new indications for common commercial and clinically approved existing drugs. For example, chloroquine, an old antimalarial drug, showed promising results for treating COVID-19, interfering with MDR in several types of cancer, and chemosensitizing human leukemic cells.This book focuses on the hypothesis, risk/benefits, and economic impacts of drug repurposing on drug discovery in dermatology, infectious diseases, neurological disorders, cancer, and orphan diseases. It brings together up-to-date research to provide readers with an informative, illustrative, and easy-to-read book useful for students, clinicians, and the pharmaceutical industry.
